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To the Editor:
We congratulate Furck and col-
leagues1 for their excellent analysis of
outcomes after the Norwood operation
in patients with hypoplastic left heart
syndrome, as described in their recent
publication. However, we are con-
cerned that the authors have reported
the rate ofmortality using a nonstandard
strategy for this type of reporting. Furck
and colleagues reported a 30-day mor-
tality of 2.5% for the last 3 years.
They stated that ‘‘Death after this period
and until the subsequent palliative sur-
gery, regardless of whether in or out of
the hospital, was defined as interstage
mortality.’’ They reported interstage
mortality of 15%. This manner of
reporting of outcomes is not consistent
with standardized reporting strategies.
It can be potentially misleading and
can create unrealistic expectations
among referring physicians, caregivers,
and families.
Collaborative international efforts
have resulted in the establishment of
standardized methodologies for the
reporting of mortality and morbidity
associated with pediatric and congen-
ital cardiac surgery.2,3 Operative
mortality is defined as any death, re-
gardless of cause, occurring (1) within
30 days after surgical intervention in
or out of the hospital and (2) after 30
days during the same hospitalization
subsequent to the operation. Thus op-
erative mortality includes all deaths726 The Journal of Thoracic and Cthat occur during the initial hospitali-
zation. Logically, interstage mortality
encompasses all deaths that occur after
the period of time included in opera-
tive mortality but before the stage 2
operation. Thus all mortality during
the initial hospitalization should be
classified as operative mortality and
not interstage mortality.
The most recent analysis of the
Society of Thoracic Surgeons Congen-
ital Heart Surgery Database documents
discharge mortality of 18.7% (447/
2395 patients) after the Norwood (stage
I) operation.4 By reporting only 30-day
mortality and classifying deaths that oc-
cur after 30 days but during the initial
hospitalization as interstage mortality,
the authors have used a methodology
not consistent with standardized meth-
odologies of outcome reporting. If an
author wishes to explore other means
of presentation, one would assume
that it would be done with a degree of
emphasis that was not apparent in this
article. We believe that the use of stan-
dard reporting strategies for mortality is
crucial when reporting the outcomes
after pediatric and congenital cardiac
surgery.
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We thank Jonas and his colleagues
for their interest in our study and for
drawing our attention to the definition
of operative mortality.1
During the review process of the
manuscript, we offered to recalculate
our data on mortality of the Nor-
wood operation according to the def-
inition of The Society of Thoracic
Surgeons Congenital Database Task-
force and the Joint EACTS–STS
Congenital Database Committee,2
but as we gave data on both 30-day
mortality and interstage mortality,
we were allowed to leave the data
as presented.
However, we agree with Jonas and
colleagues that the way of reporting
operative mortality should be consis-
tent to simplify comparison between
groups. We, therefore, recalculated0
